Phase 3 Study Outcomes in Diabetic Retinopathy
The GLOW2 study reveals the superior efficacy of Zenkuda™ (tarcocimab tedromer) over a sham procedure in treating diabetic retinopathy.
Topline Results from GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrate Superiority of Zenkuda (tarcocimab tedromer) Over Sham
Phase 3 Study Outcomes in Diabetic Retinopathy Page 2